What is the official website of AstraZeneca ?

The official website of AstraZeneca is http://www.astrazeneca.com.

What is AstraZeneca's cybersecurity risk score?

AstraZeneca has an AI-generated cybersecurity risk score of 787 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has AstraZeneca experienced?

According to Rankiteo, AstraZeneca currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has AstraZeneca been affected by any supply chain cyber incidents ?

According to Rankiteo, AstraZeneca has been affected by a supply chain cyber incident involving Clario, with the incident ID ERT18610523.

Does AstraZeneca have SOC 2 Type 1 certification ?

According to Rankiteo, AstraZeneca is not certified under SOC 2 Type 1.

Does AstraZeneca have SOC 2 Type 2 certification ?

According to Rankiteo, AstraZeneca does not hold a SOC 2 Type 2 certification.

Does AstraZeneca comply with GDPR ?

According to Rankiteo, AstraZeneca is not listed as GDPR compliant.

Does AstraZeneca have PCI DSS certification ?

According to Rankiteo, AstraZeneca does not currently maintain PCI DSS compliance.

Does AstraZeneca comply with HIPAA ?

According to Rankiteo, AstraZeneca is not compliant with HIPAA regulations.

Does AstraZeneca have ISO 27001 certification ?

According to Rankiteo,AstraZeneca is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does AstraZeneca operate in ?

AstraZeneca operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does AstraZeneca have ?

AstraZeneca employs approximately 78,683 people worldwide.

Does AstraZeneca own any subsidiaries ?

AstraZeneca presently has no subsidiaries across any sectors.

How many LinkedIn followers does AstraZeneca have ?

AstraZeneca's official LinkedIn profile has approximately 3,722,569 followers.

What is the NAICS classification code for AstraZeneca ?

AstraZeneca is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does AstraZeneca have a Crunchbase profile ?

Yes, AstraZeneca has an official profile on Crunchbase, which can be accessed here: https://www.crunchbase.com/organization/astrazeneca.

Does AstraZeneca have a LinkedIn profile ?

Yes, AstraZeneca maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/astrazeneca.

How many cybersecurity incidents has AstraZeneca experienced ?

As of October 7, 2026, Rankiteo reports that AstraZeneca has experienced 4 cybersecurity incidents.

How many peer or competitor companies does AstraZeneca have ?

AstraZeneca has an estimated 5,774 peer or competitor companies worldwide.

What types of cybersecurity incidents has AstraZeneca faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach, Vulnerability and Ransomware.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

AstraZeneca

Boost Score +25 with badge (5 left)

787

/1000

Fair

812

/1000

Good

AstraZeneca Vendor Cyber Rating & Cyber Score

astrazeneca.com

cb in

Add Your Compliance Badge

We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com. Community Guidelines: bit.ly/2MgAcio

AstraZeneca

AstraZeneca CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

AstraZeneca

Breach

3/2026

AST1774045431

AstraZeneca

Vulnerability

3/2026

AST-TESHE177367...

AstraZeneca

Breach

6/2021

AST2255131222

AstraZeneca

Ransomware

10/2020

Clario

ERT18610523

Loading…

A.I.

AstraZeneca Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for AstraZeneca

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

AstraZeneca has 38.89% more incidents than the average of same-industry companies with at least one recorded incident.

Incidents vs All-Companies Average (This Year)

AstraZeneca has 98.02% more incidents than the average of all companies with at least one recorded incident.

Incident Types AstraZeneca vs Pharmaceutical Manufacturing Industry Avg (This Year)

AstraZeneca reported 2 incidents this year: 0 cyber attacks, 0 ransomware, 1 vulnerabilities, 1 data breaches, compared to industry peers with at least 1 incident.

Incident History - AstraZeneca (X = Date, Y = Severity)

Loading…

SUBSIDIARY

AstraZeneca Subsidiaries

AstraZeneca

Pharmaceutical Manufacturing

Website: http://www.astrazeneca.com

Company Size: 10,001+ employees

AstraZeneca IndiaPharmaceutical Manufacturing

Loading…

AstraZeneca Similar Companies

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Loading…

NEWS

AstraZeneca CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

October 05, 2026 04:17 PM

AstraZeneca Opens Global R&D Centre in Cambridge’s Kendall Square

AstraZeneca's Kendall Square centre anchors a billion-dollar bet on Massachusetts as a… View more. AstraZeneca's Kendall Square centre...

Read Article

October 05, 2026 11:19 AM

AstraZeneca Closes $2 Billion Summit Therapeutics Equity Investment

AstraZeneca's $2 billion stake ties Summit's ivonescimab to a broader ADC combination… View more. AstraZeneca's $2 billion stake ties...

Read Article

October 01, 2026 11:57 PM

AstraZeneca Stocks Drops as $2 Billion Buys an Oncology Option

The Summit investment secures trial access without transferring ownership of either company's cancer medicine.

Read Article

September 29, 2026 01:38 PM

Kavitha Srinivasulu Joins Persistent Systems as Chief Cyber & AI Security Officer

Srinivasulu will oversee AI security, risk advisory, and cybersecurity and work across leadership teams at Persistent Systems.

Read Article

September 28, 2026 09:48 PM

AstraZeneca Invests $2 Billion in Summit Therapeutics Preferred Equity

AstraZeneca's $2 billion preferred equity stake gives it roughly 12.0% of Summit's… View more. AstraZeneca's $2 billion preferred equity...

Read Article

September 18, 2026 07:00 AM

AstraZeneca Efzimfotase Alfa BLA Granted FDA Priority Review in HPP

AstraZeneca. . ----. -----. said on 18 September 2026 that the US Food and Drug Administration had accepted the Biologics License...

Read Article

July 31, 2026 07:00 AM

AstraZeneca Moves Low-Carbon Inhaler Closer to EU Approval

AstraZeneca has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for...

Read Article

June 23, 2026 07:00 AM

AstraZeneca partners with South Korea’s Ezcuris and Galux on immunology and AI - CHOSUNBIZ

AstraZeneca has chosen Ezcuris, a domestic new drug development corporations for immune diseases, and the AI protein design corporations...

Read Article

May 01, 2026 07:00 AM

New VP incoming as headcount nears 50 at Leeds cybersecurity specialist

There's a new VP at BGF-backed Boxphish – a Leeds-headquartered human risk management platform – following of growth of both customer wins...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-97626

SUMMARY

Requesting a user or organization profile page (`GET /{username}`) with an `Accept: application/rss+xml` or `Accept: application/atom+xml` header returned the owner's activity feed without the visibility check that the profile page and the `.rss` and `.atom` routes apply. Anonymous users, restricted users and non-members could confirm the existence of limited or private users and private organizations and read their profile details and public activity, also when `[other] ENABLE_FEED` was disabled. Activity in private repositories was not included.

Published

Date2026-10-06

Updated

Date2026-10-06

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-97208

SUMMARY

The Gitea API endpoint for creating push mirrors (`POST /api/v1/repos/{owner}/{repo}/push_mirrors`) checked only whether mirroring was enabled and not the `[mirror] DISABLE_NEW_PUSH` setting that the web interface enforces. A repository administrator could therefore create new push mirrors on instances where the site administrator had disabled them. A push mirror pushes all refs of the repository to a remote chosen by the caller, on each commit or on a schedule.

Published

Date2026-10-06

Updated

Date2026-10-06

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-96594

SUMMARY

The Gitea API endpoint `GET /api/v1/repos/{owner}/{repo}/media/{filepath}` wrote files of up to 1 KiB that are stored directly in Git, not in LFS, to the response without the content type and disposition headers Gitea uses for user content. An HTML file committed to a repository was therefore rendered by the browser on the Gitea origin. A user who can push to a repository could run JavaScript in the session of a victim who opens the media URL and act with the victim's permissions.

Published

Date2026-10-06

Updated

Date2026-10-06

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-89182

SUMMARY

With `[repository] FORCE_PRIVATE = true`, Gitea creates new repositories as private, but the post-receive hook still applied the `repo.private=false` push option to an empty repository created by push. Any user who can create repositories could make their new repository public in violation of the instance policy. The default configuration is not affected.

Published

Date2026-10-06

Updated

Date2026-10-06

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-86684

SUMMARY

The Gitea push mirror API checked whether the repository owner, instead of the requesting user, may use local file system paths. On instances with `[security] IMPORT_LOCAL_PATHS = true`, a repository administrator who is not allowed to import local paths could add a push mirror to a local path on the server when the repository owner has that permission. Gitea then pushed the repository's refs into an existing Git repository at that path with the permissions of the Gitea process.

Published

Date2026-10-06

Updated

Date2026-10-06

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

AstraZeneca Vendor Cyber Rating & Cyber Score

AstraZeneca A.I CyberSecurity Scoring

AstraZeneca CyberSecurity News & History

AstraZeneca Company Scoring based on AI Models